New Insights into the Use of Empagliflozin—A Comprehensive Review

Empagliflozin is a relatively new drug that, as an inhibitor of the sodium–glucose cotransporter 2 (SGLT2), causes increased urinary glucose excretion and thus contributes to improved glycemic control, better glucose metabolism, reduced glucotoxicity and insulin resistance. Although its original use...

Descripción completa

Detalles Bibliográficos
Autores principales: Forycka, Joanna, Hajdys, Joanna, Krzemińska, Julia, Wilczopolski, Piotr, Wronka, Magdalena, Młynarska, Ewelina, Rysz, Jacek, Franczyk, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775057/
https://www.ncbi.nlm.nih.gov/pubmed/36552050
http://dx.doi.org/10.3390/biomedicines10123294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775057/
https://www.ncbi.nlm.nih.gov/pubmed/36552050
http://dx.doi.org/10.3390/biomedicines10123294

Ejemplares similares